Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Greenbaum

Showing results (151-160 of 225) with videos related to

Pageof 23
Sort By:
Diabetes|May 1, 1990
Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family StudyD K McCulloch, L J Klaff, S E Kahn, et al.
Frontiers in Immunology|October 2, 2019
Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal StudyCate Speake, Henry T Bahnson, Johnna D Wesley, et al.
Diabetes Care|May 2, 2012
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetesJay M Sosenko, Jay S Skyler, Jeffrey Mahon, et al.
Diabetes Care|June 18, 2011
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History StudyJay M Sosenko, Jay S Skyler, Jeffrey Mahon, et al.
Diabetes Care|February 25, 2018
Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787Jay M Sosenko, Jay S Skyler, Jeffrey Mahon, et al.
Diabetes|April 25, 2014
Molecular signatures differentiate immune states in type 1 diabetic familiesYi-Guang Chen, Susanne M Cabrera, Shuang Jia, et al.
Diabetes Care|March 12, 2015
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 monthsJay M Sosenko, Jay S Skyler, Craig A Beam, et al.
Diabetes|December 25, 2003
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001Jerry P Palmer, G Alexander Fleming, Carla J Greenbaum, et al.
JCI Insight|September 26, 2023
Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetesElisa Balmas, Janice Chen, Alex K Hu, et al.
Diabetologia|September 27, 2017
Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNetManuela Battaglia, Mark S Anderson, Jane H Buckner, et al.
Pageof 23

Showing results (151-160 of 225) with videos related to

Sort By:
Pageof 23
Diabetes|May 1, 1990
Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family StudyD K McCulloch, L J Klaff, S E Kahn, et al.
Frontiers in Immunology|October 2, 2019
Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal StudyCate Speake, Henry T Bahnson, Johnna D Wesley, et al.
Diabetes Care|May 2, 2012
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetesJay M Sosenko, Jay S Skyler, Jeffrey Mahon, et al.
Diabetes Care|June 18, 2011
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History StudyJay M Sosenko, Jay S Skyler, Jeffrey Mahon, et al.
Diabetes Care|February 25, 2018
Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787Jay M Sosenko, Jay S Skyler, Jeffrey Mahon, et al.
Diabetes|April 25, 2014
Molecular signatures differentiate immune states in type 1 diabetic familiesYi-Guang Chen, Susanne M Cabrera, Shuang Jia, et al.
Diabetes Care|March 12, 2015
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 monthsJay M Sosenko, Jay S Skyler, Craig A Beam, et al.
Diabetes|December 25, 2003
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001Jerry P Palmer, G Alexander Fleming, Carla J Greenbaum, et al.
JCI Insight|September 26, 2023
Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetesElisa Balmas, Janice Chen, Alex K Hu, et al.
Diabetologia|September 27, 2017
Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNetManuela Battaglia, Mark S Anderson, Jane H Buckner, et al.
Pageof 23